Merck KGaA Returns PKU Drugs To BioMarin To Focus On Cancer

Merck KGaA is returning to BioMarin Pharmaceutical Inc the rights to the Kuvan (sapropterin) drug against rare genetic disorder PKU as the diversified German group seeks to exit non-core areas to focus on cancer, immunology and neurology.

Merck KGaA is returning to BioMarin Pharmaceutical Inc the rights to the Kuvan (sapropterin) drug against rare genetic disorder PKU as the diversified German group seeks to exit non-core areas to focus on cancer, immunology and neurology.

Merck acquired the rights to to Kuvan and Peg-Pal, another PKU treatment in markets outside of the US and Japan,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

More from Therapy Areas

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By 

Series B cash will be used to advance its Stargardt disease gene therapy.

In Brief: PolyPid’s D-PLEX100 Aces Phase III Trial, US Partner, Submission Eyed

 

PolyPid's D-PLEX100 meets Phase III endpoints this time around, significantly reducing surgical point infections in abdominal colorectal surgery, and is set for a US approval submission early next year.

Insmed’s PAH Data Indicate Potential To Surpass Established Therapies

 
• By 

Insmed’s inhaled treprostinil exceeded goals for reducing pulmonary vascular resistance and improving six-minute walk test distance in Phase IIb data.